PomDoctor Receives Nasdaq Deficiency Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Should l Buy POM?
PomDoctor announced that it has received a written notification from the staff of Nasdaq dated January 29, indicating that for the last 33 consecutive business days, the closing bid price of the company's American depositary shares was below the minimum bid price of $1.00 per share requirement set forth in Nasdaq Listing Rule 5450. The Deficiency Letter has no current effect on the listing or trading of the company's ADSs on Nasdaq. Pursuant to Nasdaq Listing Rule 5810, the company is provided with a compliance period of 180 calendar days, or until July 28, to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the compliance period, the closing bid price of the company's ADSs is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide the company a written confirmation of compliance and the matter will be closed. In the event the company does not regain compliance by July 28, subject to the determination by the staff of Nasdaq, the company may be eligible for additional time. The deficiency letter will have no effect on the company's business operations, and the company will take all reasonable measures to regain compliance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy POM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on POM
About POM
PomDoctor Ltd is a company that mainly operates an online medical services platform for chronic diseases. The Company's business model focuses on chronic disease management and pharmaceutical services, forming a one-stop medical service platform that connects patients with doctors and pharmaceutical products. It helps patients to conveniently connect with doctors and obtain one-stop medical services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for PomDoctor Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ:POM) securities between October 9, 2025, and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, involving fraudulent stock promotion schemes and insider trading through offshore accounts, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and high success rate in this field.
See More
Investigation Launched into Pomdoctor Securities Litigation
- Legal Investigation: Faruq & Faruq, LLP is investigating potential claims against Pomdoctor Limited and urges investors to contact them before the April 13, 2026 deadline to seek lead plaintiff status, ensuring their rights in the class action are protected.
- Stock Price Plunge: Pomdoctor's stock price fell from approximately $0.50 on December 10, 2025, to about $0.38 the following day, representing a decline of roughly $0.12 or 24% in a single trading session, highlighting severe investor concerns regarding the company's financial performance.
- False Promotion Allegations: The lawsuit alleges that Pomdoctor and its executives violated federal securities laws through social media misinformation and insider trading, leading to significant losses for investors and damaging the company's reputation and market trust.
- Investor Rights Protection: Faruq & Faruq encourages anyone with information regarding Pomdoctor's conduct to come forward, including whistleblowers and former employees, to aid in the legal proceedings aimed at securing better outcomes for affected investors.
See More
PomDoctor Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and potentially receive compensation without upfront costs.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, failing to disclose a fraudulent stock promotion scheme involving social media, which led to investor losses during a price manipulation campaign, thereby damaging the company's reputation and market trust.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieved the largest securities class action settlement against a Chinese company in 2017, highlighting its leadership and success in the industry.
- Investor Guidance: The firm advises investors to select qualified counsel with a proven track record to avoid firms that merely act as intermediaries, ensuring effective legal representation and support in litigation.
See More
PomDoctor Faces Class Action Lawsuit Over Securities Fraud Allegations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against PomDoctor, seeking damages for investors who purchased securities between October 9 and December 11, 2025, reflecting strong investor concerns over potential fraud.
- Allegations of False Statements: The complaint alleges that PomDoctor failed to disclose significant adverse facts regarding its business and operations during the class period, misleading investors and highlighting severe deficiencies in corporate governance and transparency.
- Insider Trading Activities: The lawsuit further claims that insiders used offshore or nominee accounts to facilitate coordinated share dumping during price inflation campaigns, revealing improper market manipulation that could undermine investor confidence.
- Legal Implications for Investors: Investors must apply to be lead plaintiffs by April 6, 2026, indicating the urgency of the case, while Bronstein, Gewirtz & Grossman, LLC offers risk-free representation, emphasizing their commitment to protecting investor rights.
See More
Reminder for PomDoctor Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme during the class period, utilizing social media to spread misinformation that misled investors and affected stock prices.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked first in 2017 for the number of settlements, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success in leadership roles, avoiding those that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
PomDoctor Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ:POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more victims to participate.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, involving fraudulent stock promotions and insiders manipulating stock prices through offshore accounts, resulting in significant losses for investors.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having secured hundreds of millions in settlements, emphasizing the importance of selecting experienced counsel to protect investor rights.
See More
Reminder for PomDoctor Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ:POM) securities between October 9, 2025, and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Case Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, involving fraudulent stock promotion schemes and insider trading through offshore accounts, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and high success rate in this field.
See More
Investigation Launched into Pomdoctor Securities Litigation
- Legal Investigation: Faruq & Faruq, LLP is investigating potential claims against Pomdoctor Limited and urges investors to contact them before the April 13, 2026 deadline to seek lead plaintiff status, ensuring their rights in the class action are protected.
- Stock Price Plunge: Pomdoctor's stock price fell from approximately $0.50 on December 10, 2025, to about $0.38 the following day, representing a decline of roughly $0.12 or 24% in a single trading session, highlighting severe investor concerns regarding the company's financial performance.
- False Promotion Allegations: The lawsuit alleges that Pomdoctor and its executives violated federal securities laws through social media misinformation and insider trading, leading to significant losses for investors and damaging the company's reputation and market trust.
- Investor Rights Protection: Faruq & Faruq encourages anyone with information regarding Pomdoctor's conduct to come forward, including whistleblowers and former employees, to aid in the legal proceedings aimed at securing better outcomes for affected investors.
See More
PomDoctor Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 13, 2026, to participate in the class action and potentially receive compensation without upfront costs.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, failing to disclose a fraudulent stock promotion scheme involving social media, which led to investor losses during a price manipulation campaign, thereby damaging the company's reputation and market trust.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and achieved the largest securities class action settlement against a Chinese company in 2017, highlighting its leadership and success in the industry.
- Investor Guidance: The firm advises investors to select qualified counsel with a proven track record to avoid firms that merely act as intermediaries, ensuring effective legal representation and support in litigation.
See More
PomDoctor Faces Class Action Lawsuit Over Securities Fraud Allegations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against PomDoctor, seeking damages for investors who purchased securities between October 9 and December 11, 2025, reflecting strong investor concerns over potential fraud.
- Allegations of False Statements: The complaint alleges that PomDoctor failed to disclose significant adverse facts regarding its business and operations during the class period, misleading investors and highlighting severe deficiencies in corporate governance and transparency.
- Insider Trading Activities: The lawsuit further claims that insiders used offshore or nominee accounts to facilitate coordinated share dumping during price inflation campaigns, revealing improper market manipulation that could undermine investor confidence.
- Legal Implications for Investors: Investors must apply to be lead plaintiffs by April 6, 2026, indicating the urgency of the case, while Bronstein, Gewirtz & Grossman, LLC offers risk-free representation, emphasizing their commitment to protecting investor rights.
See More
Reminder for PomDoctor Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme during the class period, utilizing social media to spread misinformation that misled investors and affected stock prices.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, being ranked first in 2017 for the number of settlements, showcasing its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select law firms with proven success in leadership roles, avoiding those that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
PomDoctor Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ:POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more victims to participate.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, involving fraudulent stock promotions and insiders manipulating stock prices through offshore accounts, resulting in significant losses for investors.
- Law Firm's Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having secured hundreds of millions in settlements, emphasizing the importance of selecting experienced counsel to protect investor rights.
See More
